Compugen Ltd. (NASDAQ:CGEN) Q4 2022 Earnings Call Transcript

Henry Adewoye: Yes. Yes. It’s very likely to be listed under the same trial cohort. And it will be enrolling in the sites also that are listed — currently listed on ClinicalTrials.gov and will look the necessary public disclosures as soon as we can. We will also be looking for additional sites also, and we expect that to be on track, just like Anat mentioned in her prepared comments. I may — let me go back to Daina’s question because I think Daina asked me question on the number of prior lines that we saw on our prior disclosures at ESMO IO, for example, and also at SITC, Dr. Overman’s presentation. So let me start with ovarian cancer first, Daina. So for the ovarian cancer cohort, at ESMO IO and as you remember, we had two presentations, one by Dr. Yeku from Mass General Hospital.

Remember, this was a population of platinum-resistant ovarian cancer, and it was the drug combination, meaning COM701 plus nivolumab. The number of median number of lines in that recent population of 20 was 6. That’s the number of median parallel lines with a range of 2 to 9, okay? And then for the triplet combination that was presented by Dr. John Moroney at University of Chicago, 20 patients also. The number of median lines was four with a range of 110. We expect that most of the patients will fall within this range for this new triplet expansion cohort that will be including — that will consist of COM701, COM902 and Pembrolizumab.

Charles Butler: Thank you.

Operator: This concludes the QA session and Compugen’s investor conference call. Thank you for your participation. You may go ahead and disconnect.